Madrigal Pharmaceuticals (MDGL) PT Raised to $410 at UBS

March 15, 2024 10:38 AM

UBS analyst Eliana Merle raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $410.00 (from $337.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found